Michael P Pender

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8996574/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nature Genetics, 2009, 41, 824-828.	21.4	501
2	Genomeâ€wide metaâ€analysis identifies novel multiple sclerosis susceptibility loci. Annals of Neurology, 2011, 70, 897-912.	5.3	314
3	Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends in Immunology, 2003, 24, 584-588.	6.8	243
4	Apoptosis in the nervous system in experimental allergic encephalomyelitis. Journal of the Neurological Sciences, 1991, 104, 81-87.	0.6	234
5	CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. Autoimmune Diseases, 2012, 2012, 1-16.	0.6	195
6	Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends in Molecular Medicine, 2020, 26, 296-310.	6.7	178
7	Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Annals of Neurology, 1998, 44, 980-983.	5.3	137
8	Immune dysregulation and selfâ€reactivity in schizophrenia: Do some cases of schizophrenia have an autoimmune basis?. Immunology and Cell Biology, 2005, 83, 9-17.	2.3	127
9	Apoptosis of inflammatory cells in immune control of the nervous system: Role of glia. Glia, 2001, 36, 137-144.	4.9	122
10	Epstein–Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clinical and Translational Immunology, 2014, 3, e27.	3.8	120
11	Apoptotic elimination of Vβ8.2+ cells from the central nervous system during recovery from experimental autoimmune encephalomyelitis induced by the passive transfer of Vβ8.2+ encephalitogenic T cells. European Journal of Immunology, 1994, 24, 2609-2617.	2.9	117
12	Apoptosis of αβ T lymphocytes in the nervous system in experimental autoimmune encephalomyelitis: Its possible implications for recovery and acquired tolerance. Journal of Autoimmunity, 1992, 5, 401-410.	6.5	114
13	VARIATION IN THE VITAMIN D RECEPTOR GENE IS ASSOCIATED WITH MULTIPLE SCLEROSIS IN AN AUSTRALIAN POPULATION. Journal of Neurogenetics, 2005, 19, 25-38.	1.4	114
14	The Essential Role of Epstein-Barr Virus in the Pathogenesis of Multiple Sclerosis. Neuroscientist, 2011, 17, 351-367.	3.5	113
15	Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 632-638.	1.9	108
16	Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis. JCI Insight, 2018, 3, .	5.0	105
17	The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. Journal of Clinical Neuroscience, 2000, 7, 434-437.	1.5	102
18	Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet. The, 1998, 351, 978-981.	13.7	99

#	Article	IF	CITATIONS
19	Defective Tâ€eell control of Epstein–Barr virus infection in multiple sclerosis. Clinical and Translational Immunology, 2017, 6, e126.	3.8	90
20	Improvement in chronic hepatocerebral degeneration following liver transplantation. Gastroenterology, 1990, 98, 1079-1082.	1.3	88
21	Latitudinal variation in incidence and type of first central nervous system demyelinating events. Multiple Sclerosis Journal, 2010, 16, 398-405.	3.0	80
22	Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: Results from the Ausimmune Study. Multiple Sclerosis Journal, 2016, 22, 884-892.	3.0	80
23	Immunology of multiple sclerosis. Current Allergy and Asthma Reports, 2007, 7, 285-292.	5.3	79
24	The role of latitude, ultraviolet radiation exposure and vitamin D in childhood asthma and hayfever: an Australian multicenter study. Pediatric Allergy and Immunology, 2011, 22, 327-333.	2.6	78
25	Vitamin D status: Multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 300-308.	2.5	78
26	Macrophage Apoptosis in the Central Nervous System in Experimental Autoimmune Encephalomyelitis. Journal of Autoimmunity, 1994, 7, 145-152.	6.5	74
27	Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance. Immunology and Cell Biology, 1999, 77, 216-223.	2.3	68
28	Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function. Multiple Sclerosis Journal, 2007, 13, 827-839.	3.0	68
29	A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction. Acta Neuropathologica, 2000, 100, 174-182.	7.7	67
30	Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1541-1544.	3.0	67
31	The roles of Fas, Fas ligand and Bcl-2 in T cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 1998, 82, 47-55.	2.3	63
32	Antigen-specific down-regulation of myelin basic protein-reactive T cells during spontaneous recovery from experimental autoimmune encephalomyelitis: further evidence of apoptotic deletion of autoreactive T cells in the central nervous system. International Immunology, 1995, 7, 967-973.	4.0	62
33	Surges of Increased T Cell Reactivity to an Encephalitogenic Region of Myelin Proteolipid Protein Occur More Often in Patients with Multiple Sclerosis Than in Healthy Subjects. Journal of Immunology, 2000, 165, 5322-5331.	0.8	62
34	Microglia are more susceptible than macrophages to apoptosis in the central nervous system in experimental autoimmune encephalomyelitis through a mechanism not involving Fas (CD95). International Immunology, 1998, 10, 935-941.	4.0	61
35	Preventing and curing multiple sclerosis by controlling Epstein–Barr virus infection. Autoimmunity Reviews, 2009, 8, 563-568.	5.8	60
36	Increased Apoptosis of T Lymphocytes and Macrophages in the Central and Peripheral Nervous Systems of Lewis Rats with Experimental Autoimmune Encephalomyelitis Treated with Dexamethasone. Journal of Neuropathology and Experimental Neurology, 1997, 56, 58-69.	1.7	59

#	Article	IF	CITATIONS
37	Blood–brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement. Journal of Neuroimmunology, 2005, 160, 162-169.	2.3	59
38	Population attributable fractions and joint effects of key risk factors for multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 461-469.	3.0	59
39	Ascending impairment of nociception in rats with experimental allergic encephalomyelitis. Journal of the Neurological Sciences, 1986, 75, 317-328.	0.6	58
40	Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. Journal of Clinical Neuroscience, 2003, 10, 63-66.	1.5	57
41	Deficiency of CD8 ⁺ effector memory T cells is an early and persistent feature of multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1825-1832.	3.0	57
42	Demyelination and neurological signs in experimental allergic encephalomyelitis. Journal of Neuroimmunology, 1987, 15, 11-24.	2.3	53
43	Associations between Silicone Skin Cast Score, Cumulative Sun Exposure, and Other Factors in the Ausimmune Study: A Multicenter Australian Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2887-2894.	2.5	52
44	The pathophysiology of myelin basic protein-induced acute experimental allergic encephalomyelitis in the Lewis rat. Journal of the Neurological Sciences, 1988, 86, 277-289.	0.6	50
45	The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A. Acta Neuropathologica, 1990, 80, 172-183.	7.7	49
46	The effects of prophylactic cyclosporin A on experimental allergic neuritis (EAN) in the Lewis rat. Induction of relapsing EAN using low dose cyclosporin A. Journal of Neuroimmunology, 1990, 28, 131-140.	2.3	45
47	Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of Vβ8.2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of Vβ8.2+ cells. Journal of Neuroimmunology, 1996, 70, 93-101.	2.3	44
48	Familial occurrence of multiple sclerosis with thyroid disease and systemic lupus erythematosus. Journal of the Neurological Sciences, 1990, 97, 163-171.	0.6	42
49	Inflammatory cells, microglia and MHC class II antigen-positive cells in the spinal cord of Lewis rats with acute and chronic relapsing experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 1994, 51, 153-167.	2.3	41
50	Myelin proteolipid protein: An effective autoantigen and target of autoimmunity in multiple sclerosis. Journal of Autoimmunity, 2008, 31, 281-287.	6.5	40
51	T-cell apoptosis in human glioblastoma multiforme: Implications for immunotherapy. Journal of Neuroimmunology, 2006, 175, 59-68.	2.3	39
52	Correlation of Blood T Cell and Antibody Reactivity to Myelin Proteins with HLA Type and Lesion Localization in Multiple Sclerosis. Journal of Immunology, 2008, 180, 6402-6410.	0.8	39
53	Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs. European Journal of Immunology, 1998, 28, 1626-1635.	2.9	36
54	A Higher Mediterranean Diet Score, Including Unprocessed Red Meat, Is Associated with Reduced Risk of Central Nervous System Demyelination in a Case-Control Study of Australian Adults. Journal of Nutrition, 2019, 149, 1385-1392.	2.9	36

#	Article	IF	CITATIONS
55	Conduction block in the peripheral nervous system in experimental allergic encephalomyelitis. Nature, 1982, 296, 860-862.	27.8	35
56	The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair?. Journal of Clinical Neuroscience, 2004, 11, 689-692.	1.5	35
57	The pathophysiology of acute experimental allergic encephalomyelitis induced by whole spinal cord in the Lewis rat. Journal of the Neurological Sciences, 1988, 84, 209-222.	0.6	34
58	Involvement of the dorsal root ganglion in acute experimental allergic encephalomyelitis in the Lewis rat. Journal of the Neurological Sciences, 1986, 72, 231-242.	0.6	33
59	Clinical and histological findings in proteolipid protein-induced experimental autoimmune encephalomyelitis (EAE) in the lewis rat. Distribution of demyelination differs from that in EAE induced by other antigens. Journal of the Neurological Sciences, 1994, 123, 154-161.	0.6	33
60	Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis. Inflammation and Allergy: Drug Targets, 2004, 3, 279-290.	3.1	32
61	Acute transverse myelitis after tetanus toxoid vaccination. Lancet, The, 1992, 339, 1111-1112.	13.7	31
62	Effect of gender on T-cell proliferative responses to myelin proteolipid protein antigens in patients with multiple sclerosis and controls. Journal of Autoimmunity, 2004, 22, 345-352.	6.5	31
63	Closing the case of <i>APOE</i> in multiple sclerosis: no association with disease risk in over 29â€000 subjects: Figure 1. Journal of Medical Genetics, 2012, 49, 558-562.	3.2	31
64	Expression of CD45RC and Ia antigen in the spinal cord in acute experimental allergic encephalomyelitis: An immunocytochemical and flow cytometric study. Journal of the Neurological Sciences, 1992, 113, 177-186.	0.6	30
65	Does Epstein-Barr virus infection in the brain drive the development of multiple sclerosis?. Brain, 2009, 132, 3196-3198.	7.6	30
66	The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: The Ausimmune study. Multiple Sclerosis Journal, 2013, 19, 1717-1725.	3.0	30
67	Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course. Frontiers in Neurology, 2018, 9, 16.	2.4	30
68	CD8 T cell deficiency impairs control of Epstein–Barr virus and worsens with age in multiple sclerosis: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 353-354.	1.9	29
69	Demyelination and early remyelination in experimental allergic encephalomyelitis passively ransferred with myelin basic protein-sensitized lymphocytes in the Lewis rat. Journal of Neuroimmunology, 1989, 25, 125-142.	2.3	28
70	Rapid entry and downregulation of T cells in the central nervous system during the reinduction of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2001, 112, 15-27.	2.3	27
71	Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain–Barré syndrome. Journal of Clinical Neuroscience, 2005, 12, 409-415.	1.5	27
72	The proximal peripheral nervous system is a major site of demyelination in experimental autoimmune encephalomyelitis induced in the Lewis rat by a myelin basic protein-specific T cell clone. Acta Neuropathologica, 1995, 89, 527-531.	7.7	26

#	Article	IF	CITATIONS
73	Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects. Internal Medicine Journal, 2002, 32, 554-563.	0.8	26
74	Cytokine expression by inflammatory cells obtained from the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis induced by inoculation with myelin basic protein and adjuvants. Journal of Neuroimmunology, 1998, 88, 30-38.	2.3	25
75	B cell Apoptosis in the Central Nervous System in Experimental Autoimmune Encephalomyelitis: Roles of B cell CD95, CD95L and Bcl-2 Expression. Journal of Autoimmunity, 2000, 14, 195-204.	6.5	24
76	Conduction block due to demyelination at the ventral root exit zone in experimental allergic encephalomyelitis. Brain Research, 1986, 367, 398-401.	2.2	23
77	Genetic investigation of methylenetetrahydrofolate reductase (MTHFR) and catechol-O-methyl transferase (COMT) in multiple sclerosis. Brain Research Bulletin, 2006, 69, 327-331.	3.0	23
78	No association between MTHFR A1298C and MTRR A66G polymorphisms, and MS in an Australian cohort. Journal of the Neurological Sciences, 2007, 252, 49-52.	0.6	23
79	Sun Exposure over a Lifetime in Australian Adults from Latitudinally Diverse Regions. Photochemistry and Photobiology, 2013, 89, 737-744.	2.5	22
80	Effects of cyclosporin A treatment on clinical course and inflammatory cell apoptosis in experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. Journal of Neuroimmunology, 1999, 97, 60-69.	2.3	21
81	Strains of Epstein-Barr virus infecting multiple sclerosis patients. Multiple Sclerosis Journal, 2010, 16, 643-651.	3.0	21
82	Reported Changes in Dietary Behavior Following a First Clinical Diagnosis of Central Nervous System Demyelination. Frontiers in Neurology, 2018, 9, 161.	2.4	21
83	Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia. Journal of Neuroimmunology, 2014, 269, 68-75.	2.3	19
84	A study of human T-cell lines generated from multiple sclerosis patients and controls by stimulation with peptides of myelin basic protein. Journal of Neuroimmunology, 1996, 70, 65-74.	2.3	18
85	Dysarthria and dysphagia due to the opercular syndrome in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 817-819.	3.0	18
86	Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein–Barr Virus-Specific T Cell Therapy. Frontiers in Neurology, 2021, 12, 652811.	2.4	18
87	Conduction abnormalities are restricted to the central nervous system in experimental autoimmune encephalomyelitis induced by inoculation with proteolipid protein but not with myelin basic protein. Brain, 1994, 117, 975-986.	7.6	17
88	4: Multiple sclerosis. Medical Journal of Australia, 2000, 172, 556-562.	1.7	17
89	Treating autoimmune demyelination by augmenting lymphocyte apoptosis in the central nervous system. Journal of Neuroimmunology, 2007, 191, 26-38.	2.3	17
90	Interleukin-6 Gene Promoter-572 C Allele May Play a Role in Rate of Disease Progression in Multiple Sclerosis. International Journal of Molecular Sciences, 2012, 13, 13667-13679.	4.1	17

#	Article	IF	CITATIONS
91	Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis Journal, 2013, 19, 1355-1358.	3.0	17
92	Occupational Exposure and Risk of Central Nervous System Demyelination. American Journal of Epidemiology, 2013, 177, 954-961.	3.4	17
93	Early-life hygiene-related factors affect risk of central nervous system demyelination and asthma differentially. Clinical and Experimental Immunology, 2013, 172, 466-474.	2.6	17
94	A simple method for high resolution light microscopy of nervous tissue. Journal of Neuroscience Methods, 1985, 15, 213-218.	2.5	16
95	Autoimmune hypothyroidism associated with interferon betaâ€1b treatment in two patients with multiple sclerosis. Australian and New Zealand Journal of Medicine, 2000, 30, 278-279.	0.5	16
96	CTLA-4 single-nucleotide polymorphisms in a Caucasian population with schizophrenia. Brain, Behavior, and Immunity, 2009, 23, 347-350.	4.1	16
97	Hypothermia due to an ascending impairment of shivering in hyperacute experimental allergic encephalomyelitis in the Lewis rat. Journal of the Neurological Sciences, 1989, 94, 231-240.	0.6	15
98	Investigation of an inducible nitric oxide synthase gene (NOS2A) polymorphism in a multiple sclerosis population. Brain Research Bulletin, 2004, 64, 9-13.	3.0	15
99	Decreased CD8+T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes. BMC Neurology, 2011, 11, 95.	1.8	14
100	Adherence to <scp>MRI</scp> protocol consensus guidelines in multiple sclerosis: An <scp>A</scp> ustralian multiâ€centre study. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 594-598.	1.8	14
101	Stressful life events and the risk of initial central nervous system demyelination. Multiple Sclerosis Journal, 2017, 23, 1000-1007.	3.0	14
102	Correlation Between Anti-Myelin Proteolipid Protein (PLP) Antibodies and Disease Severity in Multiple Sclerosis Patients With PLP Response-Permissive HLA Types. Frontiers in Immunology, 2020, 11, 1891.	4.8	14
103	Demyelination of the Peripheral Nervous System Causes Neurologic Signs in Myelin Basic Protein-Induced Experimental Allergic Encephalomyelitis Annals of the New York Academy of Sciences, 1988, 540, 732-734.	3.8	13
104	Assessment of Demyelination in Glycol Methacrylate Sections: A New Protocol for Cresyl Fast Violet Staining. Biotechnic & Histochemistry, 1989, 64, 163-167.	0.4	13
105	Spinal cord disease due to melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 175-176.	1.8	13
106	Increased constitutive activation of NF-κB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis. Journal of Neuroimmunology, 2018, 320, 111-116.	2.3	13
107	Is Wikipedia unsuitable as a clinical information resource for medical students?. Medical Teacher, 2009, 31, 1095-6.	1.8	13
108	CONNECTIVE TISSUE DISEASE MIMICKING MULTIPLE SCLEROSIS. Australian and New Zealand Journal of Medicine, 1989, 19, 469-472.	0.5	12

#	ARTICLE	IF	CITATIONS
109	An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population. Brain Research, 2009, 1255, 148-152.	2.2	12
110	Experimental autoimmune encephalomyelitis. , 1995, , 26-88.		12
111	AN INTRACRANIAL ARTERIOVENOUS MALFORMATION AND PALATAL MYOCLONUS RELATED TO PSEUDOXANTHOMA ELASTICUM. Australian and New Zealand Journal of Medicine, 1989, 19, 141-143.	0.5	11
112	Neuropathological findings in chronic relapsing experimental allergic neuritis induced in the Lewis rat by inoculation with intradural root myelin and treatment with low dose cyclosporin A. Neuropathology and Applied Neurobiology, 1992, 18, 171-187.	3.2	11
113	Survival and mitosis of myelinating oligodendrocytes in experimental autoimmune encephalomyelitis: an immunocytochemical study with Rip antibody. Acta Neuropathologica, 1999, 98, 39-47.	7.7	11
114	Cyclosporin A treatment modulates cytokine mRNA expression by inflammatory cells extracted from the spinal cord of rats with experimental autoimmune encephalomyelitis induced by inoculation with myelin basic protein. Journal of the Neurological Sciences, 2001, 187, 7-16.	0.6	11
115	Apneusis responding to buspirone in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 705-707.	3.0	11
116	Prominent brainstem and cerebellar involvement in multiple sclerosis with psoriasis. Multiple Sclerosis Journal, 2009, 15, 763-766.	3.0	10
117	High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1112-1124.	3.0	10
118	Investigation of a neuronal nitric oxide synthase gene (NOS1) polymorphism in a multiple sclerosis population. Journal of the Neurological Sciences, 2004, 218, 25-28.	0.6	9
119	Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110197.	1.0	9
120	Progressive visual loss: an unusual presentation of multiple sclerosis. Journal of Clinical Neuroscience, 1996, 3, 264-267.	1.5	8
121	Reactivity to Novel Autoantigens in Patients with Coexisting Central Nervous System Demyelinating Disease and Autoimmune Thyroid Disease. Frontiers in Immunology, 2017, 8, 514.	4.8	8
122	Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset. Frontiers in Neurology, 2018, 9, 418.	2.4	8
123	Restoration of conduction in the spinal roots correlates with clinical recovery from experimental autoimmune encephalomyelitis. Muscle and Nerve, 1995, 18, 1093-1100.	2.2	7
124	Recent progress in the diagnosis and treatment of multiple sclerosis. Journal of Clinical Neuroscience, 1999, 6, 367-372.	1.5	7
125	Hypothesis: bipolar disorder is an Epstein–Barr virusâ€ d riven chronic autoimmune disease – implications for immunotherapy. Clinical and Translational Immunology, 2020, 9, e1116.	3.8	7
126	Developing a clinical–environmental–genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome. Brain Communications, 2021, 3, fcab288.	3.3	7

#	Article	IF	CITATIONS
127	Cronkhiteâ€Canada syndrome associated with peripheral neuropathy. Australian and New Zealand Journal of Medicine, 1991, 21, 379-379.	O.5	6
128	Oligodendrocyte apoptosis before immune attack in multiple sclerosis?. Annals of Neurology, 2005, 57, 158-158.	5.3	6
129	Allelic variation investigation of the estrogen receptor within an Australian multiple sclerosis population. Journal of the Neurological Sciences, 2007, 252, 9-12.	0.6	6
130	CD8+ T cells far predominate over CD4+ T cells in healthy immune response to Epstein-Barr virus infected lymphoblastoid cell lines. Blood, 2012, 120, 5085-5087.	1.4	6
131	Epstein–Barr virus-specific adoptive immunotherapy: a new horizon for multiple sclerosis treatment?. Immunotherapy, 2014, 6, 659-661.	2.0	6
132	A simple technique for flat osmicating and flat embedding of immunolabelled vibratome sections of the rat spinal cord for light and electron microscopy. Journal of Neuroscience Methods, 1996, 65, 51-54.	2.5	5
133	Intestinal pseudo-obstruction complicating multiple sclerosis. Internal Medicine Journal, 2005, 35, 191-192.	0.8	5
134	Multiple Sclerosis with Idiopathic Dilated Cardiomyopathy: A Case Report. European Neurology, 2005, 53, 214-215.	1.4	5
135	NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. Journal of Neurology, 2022, 269, 836-845.	3.6	5
136	An introduction to neuroimmunology. , 1995, , 14-25.		5
137	Acute disseminated encephalomyelitis. , 1995, , 155-165.		5
138	Focal conduction block in the dorsal root ganglion in experimental allergic neuritis. Annals of Neurology, 1992, 31, 27-33.	5.3	4
139	Baló's concentric sclerosis in a woman from Papua New Guinea. Journal of Clinical Neuroscience, 1999, 6, 46-48.	1.5	4
140	Investigation of the [â^'/A]8and C1236T genetic variations within the human toll-like receptor 3 gene for association with multiple sclerosis. Neurological Research, 2010, 32, 438-441.	1.3	4
141	Cervical selfâ€manipulation and stroke. Medical Journal of Australia, 1993, 158, 290-290.	1.7	4
142	Recent advances in the understanding, diagnosis and management of multiple sclerosis. Australian and New Zealand Journal of Medicine, 1996, 26, 157-161.	0.5	2
143	CSF testing for multiple sclerosis. Lancet Neurology, The, 2005, 4, 522-523.	10.2	2
144	Reduced lκB-α Protein Levels in Peripheral Blood Cells of Patients with Multiple Sclerosis—A Possible Cause of Constitutive NF-κB Activation. Journal of Clinical Medicine, 2020, 9, 2534.	2.4	2

#	Article	IF	CITATIONS
145	The stiff-man syndrome. , 1995, , 166-176.		2
146	The use of interferon beta at the time of initial diagnosis of multiple sclerosis. Journal of Clinical Neuroscience, 2001, 8, 381-382.	1.5	1
147	Restricted diffusion on MR imaging of an acute cerebral lesion. Journal of Clinical Neuroscience, 2008, 15, 456.	1.5	1
148	Epstein-Barr Virus and Autoimmunity. , 2004, , 163-170.		1
149	Neurological signs in inflammatory demyelination. Annals of Neurology, 1993, 33, 559-559.	5.3	Ο
150	Conduction abnormalities are restricted to the central nervous system in experimental autoimmune encephalomyelitis induced by inoculation with proteolipid protein but not with myelin basic protein. Brain, 1995, 118, 1073-1073.	7.6	0
151	Interferon beta in the management of multiple sclerosis. Australian and New Zealand Journal of Medicine, 1996, 26, 343-343.	0.5	0
152	Immunoneurology. Journal of Clinical Neuroscience, 1999, 6, 272-273.	1.5	0
153	Lower motor neuron weakness after diving-related decompression. Neurology, 2006, 66, 451-452.	1.1	О
154	Study of leukemia inhibitory factor polymorphism within an Australian multiple sclerosis population. Journal of the Neurological Sciences, 2009, 280, 62-64.	0.6	0
155	Epstein–Barr virus in the multiple sclerosis brain – An evasive culprit. Multiple Sclerosis and Related Disorders, 2012, 1, 61-63.	2.0	0
156	Paraneoplastic neurological disorders. , 1995, , 327-344.		0
157	The proximal peripheral nervous system is a major site of demyelination in experimental autoimmune encephalomyelitis induced in the Lewis rat by a myelin basic protein-specific T cell clone. Acta Neuropathologica, 1995, 89, 527-531.	7.7	Ο